-
April 2026: This Month in Huntington’s Disease Research
Latest News
-
Gene silencing for HD: the story so far
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
-
Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-
What do sheep brains have to do with HD?
How smart are sheep, and why do HD researchers care?
-
Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-
CHDI Report: Day 3
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
-
CHDI Report: Day 2
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
-
CHDI Report: Day 1
Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene
-
Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way
Anti-nausea drug meclizine protects cells with the HD mutation from death by reducing cellular energy production
-
HDBuzz takes your questions to the annual therapeutics meeting of CHDI
HDBuzz visits Palm Springs to talk with CHDI about the latest HD research. Send us your questions!
-
Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
